Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Improved Use of Antibiotic Guidelines in Hospital Environment

This study has been completed.
Information provided by:
Katholieke Universiteit Leuven Identifier:
First received: August 7, 2007
Last updated: December 17, 2010
Last verified: July 2010

The purpose of this study is to determine if the use of antibiotic guidelines and thus antibiotics can be improved through a description of possible barriers leading to tailored interventions.

Community-Acquired Pneumonia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Improved Use of Antibiotic Guidelines in in Hospital Environment: Research on an Implementation Model and the Role of the Hospital Pharmacist.

Resource links provided by NLM:

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 823
Study Start Date: October 2007
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients admitted to the hospital with a diagnosis of community-acquired pneumonia or community-acquired pyelonephritis


Inclusion Criteria:

  • Diagnosed community-acquired pneumonia (CAP)
  • Diagnosed community-acquired pyelonephritis

Exclusion Criteria:

  • CAP: hospital-acquired pneumonia; patients transferred from other hospital; death within 24h, aspiration pneumonia, immunocompromised status, palliative status, admission due to social reasons
  • Pyelonephritis: urinary tract with functional or physical abnormalities, urinary catheterisation, pregnancy, (immunocompromised status, palliative status, admission due to social reasons and history of renal transplant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00512772

Ziekenhuis Oost-Limburg
Genk, Belgium, 3600
Universitair Ziekenhuis Gasthuisberg
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Principal Investigator: Pieter-Jan Cortoos, PharmD Katholieke Universiteit Leuven
Study Director: Gert Laekeman, PhD Katholieke Universiteit Leuven
  More Information

No publications provided

Responsible Party: Pieter-Jan Cortoos, PharmD, Katholieke Universiteit Leuven Identifier: NCT00512772     History of Changes
Other Study ID Numbers: B32220072383
Study First Received: August 7, 2007
Last Updated: December 17, 2010
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Katholieke Universiteit Leuven:
Time series

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections processed this record on November 24, 2014